A5041878680- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Male Breast Health Studies
- Sarcoma Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Ferroptosis and cancer prognosis
- Bone Tumor Diagnosis and Treatments
- Lung Cancer Research Studies
- Bladder and Urothelial Cancer Treatments
- Cancer therapeutics and mechanisms
- Oral and Maxillofacial Pathology
- Ovarian cancer diagnosis and treatment
- Intraperitoneal and Appendiceal Malignancies
- Complementary and Alternative Medicine Studies
- Neuroendocrine Tumor Research Advances
- Parathyroid Disorders and Treatments
- Inflammatory Biomarkers in Disease Prognosis
- Herbal Medicine Research Studies
- Pharmacological Effects of Natural Compounds
Hacettepe University
2022-2025
Hacettepe University Hospital
2023-2024
Cancer Institute (WIA)
2024
Abstract Introduction Parathyroid carcinoma is a rare endocrine malignancy, accounting for small fraction of primary hyperparathyroidism (PHPT) cases. Its rarity complicates diagnosis due to overlapping symptoms with benign conditions and challenges in pathological examination. Limited cases result insufficient data on optimal treatment strategies outcomes. Clinical Case A 49-year-old male history symptomatic four years earlier was referred recurring hypercalcemia. His initial imaging scans...
Background: Metastatic bladder cancer (mBC) presents a significant global health challenge with poor prognosis and considerably limited survival. Despite advancements in therapies, long-term survival remains difficult to predict. This study aimed evaluate the prognostic potential of various pretreatment blood-based biomarkers, including NLR, dNLR, LMR, PLR, SII, mGPS, CAR, AGR, PNI, PIV, Bellmunt score, mBC patients. Methods: A retrospective cohort 133 patients from Hacettepe University...
Aim: To assess the prognostic role of CA-125 elimination rate constant K (KELIM) score in platinum-resistant/refractory ovarian cancer patients receiving second-line treatment. Methods: A retrospective study was carried out including 117 with advanced-stage treated liposomal doxorubicin ± bevacizumab. The KELIM score, calculated using measurements within first 100 days chemotherapy, used. Survival analyses were performed for overall survival (OS) and progression-free (PFS). Results: Higher...
Aims: Giant cell tumor of bone (GCTB) is an uncommon, benign, but aggressive osteolytic skeletal neoplasm young adults. Although denosumab frequently used in neoadjuvant treatment and metastatic unresectable disease these patients, its role adjuvant therapy unclear. In this study, we evaluated the efficacy safety as patients with resectable high-risk GCTB. Methods: Patients GCTB over age 16 who received postoperative between January 2013 September 2022 were included. Demographic clinical...
Aims: This study aimed to assess the habits and knowledge of cancer patients regarding use herbal medicines dietary supplements in receiving immune checkpoint inhibitors (ICI). Methods: The data 181 who were over 18 years old received ICIs collected. usage patterns, anticipated benefits harms, sources supply evaluated by filling researcher-prepared forms. Results: Most did not any kind medicine (91.2%) or (75.9%) during their immunotherapy. Boosting system is primary motivation for among...